Company intelligence / Profile preview

Tianyuan Capital Development

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Tian Yuan Capital is a leading healthcare-focused private equity and venture capital firm based in China. Established in 2015, the firm specializes in investments across the life sciences sector, including innovative drug development, medical devices, and healthcare services. Tian Yuan Capital has a strong track record of supporting high-growth biotech companies, with a portfolio that includes prominent names such as Innovent Biologics, CStone Pharmaceuticals, and Remegen. The firm provides not only capital but also strategic guidance and industry resources to help its portfolio companies achieve commercial success and global expansion.

Industry: Investors

Beyond the preview

Go deeper on Tianyuan Capital Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianyuan Capital Development.

Explore the full profile